BeStock  
Stocks › Infectious Disease › AZN

AstraZeneca AZN

US equityMarket cap rank #49Infectious Disease
$186.43 −$0.42 (-0.22%)
Market closed · Nov 6, 8:10 pm ET · Last extended-hours $185.92 -0.27%
Open$181.34
Prev close$186.85
Day range$181.20 – $187.33
Volume2.85M
Market cap$289.14B
P/E (TTM)26.4
Dividend yield1.73%

Earnings

Average move on report day±2.9%last 16 reports
Closed higher14 of 1688% of the time
Best reaction+7.0%
Worst reaction-0.8%

Stock move on the day after each report

+4.7%2023/Q2+0.9%2023/Q3+5.4%2024/Q1+0.6%2024/Q3+2.0%2024/Q4+2.5%2025/Q1+3.0%2025/Q2+3.2%2025/Q3+2.9%2025/Q4-0.8%2026/Q1+0.2%2026/Q2+7.0%2026/Q3
QuarterReport dateTimingImplied moveActual moveVersus implied
2026/Q330 Oct 2026None±5.2%+7.02%Bigger than priced
2026/Q227 Jul 2026None±5.6%+0.22%Within range
2026/Q129 Apr 2026Pre Market±5.0%-0.79%Within range
2025/Q410 Feb 2026Pre Market±5.4%+2.87%Within range
2025/Q36 Nov 2025Pre Market±3.8%+3.23%Within range
2025/Q229 Jul 2025Pre Market±3.9%+2.99%Within range
2025/Q129 Apr 2025Pre Market±5.1%+2.55%Within range
2024/Q46 Feb 2025None±5.2%+2.01%Within range
2024/Q312 Nov 2024Pre Market±5.6%+0.62%Within range
2024/Q125 Apr 2024None±4.5%+5.38%Bigger than priced
2023/Q39 Nov 2023Pre Market±3.4%+0.88%Within range
2023/Q228 Jul 2023Pre Market±3.6%+4.71%Bigger than priced
2023/Q127 Apr 2023None±3.5%+0.18%Within range
2022/Q49 Feb 2023None±3.8%+4.79%Bigger than priced
2022/Q310 Nov 2022None±4.3%+6.67%Bigger than priced
2022/Q229 Jul 2022None±4.1%-0.74%Within range

"Implied move" is the size of move the options market was pricing ahead of the report. Move is the stock’s change on the first session after the release.

Where the revenue comes from

Quarter 2025/FY

By region

  • US$23.97B 40.8%
  • China$6.64B 11.3%
  • Other$5.03B 8.6%
  • UK$4.36B 7.4%
  • Rest of Europe$4.32B 7.4%
  • Japan$3.56B 6.1%
  • Germany$2.89B 4.9%
  • Asia, Africa and Australasia$2.72B 4.6%
  • The Americas$2.63B 4.5%
  • Sweden$2.62B 4.5%

Fundamentals

Full statements →

Latest reported quarter: Q2, ended Jun 2026

Revenue$15.38B+6.4% YoY
Operating profit$3.16B-9.8% YoY
Net profit$2.51B+2.5% YoY
Diluted EPS$1.61+2.5% YoY
Free cash flow-$240.00M-116.4% YoY
Operating cash flow$2.87B

Revenue, last 8 quarters

$13.6BSep '24$14.9BDec '24$13.6BMar '25$14.5BJun '25$15.2BSep '25$15.5BDec '25$15.3BMar '26$15.4BJun '26

Net profit, last 8 quarters

$1.4BSep '24$1.5BDec '24$2.9BMar '25$2.4BJun '25$2.5BSep '25$2.3BDec '25$3.1BMar '26$2.5BJun '26

Profitability & balance sheet

Gross margin81.9%
Operating margin22.1%
Net margin17.0%
Return on equity22.0%
Return on assets9.2%
Return on invested capital14.4%
Current ratio0.89
Liabilities / assets56.5%
Cash & investments$4.97B
Total debt$31.81B
Net cash (debt)-$26.85B
Free cash flow / sales9.8%

Discussion

No comments yet — be the first to weigh in on AZN.

Sign in to join the discussion.

Scroll to Top